COMP <GO>
TRMB vs TMO // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Trimble Inc. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: TRMB 5
— TMO 10
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: TMO
LAST: $64.94 (-0.61%) • MKT CAP: $15.24B
options-implied-move
7.10%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
options-implied-move
6.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TRMB VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TRMB | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.10% | 41.00% | +28.10 | TRMB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.70% | 9.30% | -2.60 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 26.7x | 30.4x | -3.70 | TRMB | /valuation <GO> |
| Free Cash Flow Yield | 2.37% | 2.40% | -0.03 | TMO | /fcf-yield <GO> |
| Operating Margin | 16.50% | 17.40% | -0.90 | TMO | /operating-margins <GO> |
| Net Profit Margin | 11.80% | 15.10% | -3.30 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -2.60% | 3.90% | -6.50 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.75 | 4.50 | -0.75 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.10% | 6.70% | +0.40 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.2 | 59.1 | +8.02 | TRMB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.94 | +0.13 | TRMB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.4x | 36.3x | -2.90 | TRMB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $15.24B | $262.22B | -$246.98B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TRMB REV | TMO REV | TRMB GROSS % | TMO GROSS % | TRMB FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.59B | $44.56B | 69.1% | 44.0% | $360.9M | $6.29B |
| FY 2024 | $3.68B | $42.88B | 65.1% | 44.0% | $497.8M | $7.27B |
| FY 2023 | $3.80B | $42.86B | 44.0% | 44.0% | $426.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TRMB // BETA 1.07
TMO // BETA 0.94